Latest Breaking News On - Andrew zhu - Page 5 : comparemela.com

I-Mab Biopharma (IMAB) Provides Business and Corporate Updates, Reports Q4

I-Mab Biopharma (IMAB) Provides Business and Corporate Updates, Reports Q4
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaSan diegoUnited statesHong kongGigi fengJingwu zangRichard yehAndrew zhuEuropean society for medical oncologyCorporate developmentPipeline developmentMorgan stanley capital internationalResearch development expensesAmerican society of clinical oncologyWomen leadership councilCompany american depositary

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

Strategic reprioritization of the Company s pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting.

South koreaSan diegoUnited statesHong kongGigi fengAndrew zhuRichard yehGenexine neoimmunetechJingwu zangCorporate developmentHolding foreign companies accountableCompany responses to recentCompany american depositaryHolding foreign companies accountable actPipeline developmentEuropean society for medical oncology

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesNew orleansHong kongSan diegoMacau generalChunkang changEmilie wuAndrew zhuGigi fengFanny zhangRichard yehPrnewswire the company nasdaqErnestn morial convention centerPiacente group incExchange commissionAmerican society of hematology

I-Mab Biopharma (IMAB) Approved in China to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine

I-Mab Biopharma (IMAB) Approved in China to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Andrew zhuChina national medical products administrationCompany nasdaqEuropean society for medical oncologyDrug evaluationNational medical products administrationEuropean societyMedical oncology

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company co.

United statesHong kongSan diegoAndrew zhuGigi fengRichard yehPrnewswire the company nasdaqPiacente group incExchange commissionChina national medical products administrationEuropean society for medical oncologyDrug evaluationNational medical products administrationEuropean societyMedical oncologyPrivate securities litigation reform act